To evaluate the effect of tumor capsule rupture on disease prognosis in stage I epithelial ovarian cancer. 
pithelial ovarian cancer is the second most common gynecologic malignancy in the United States. In 2008, an estimated 21,650 new cases will be diagnosed and an estimated 15,520 women will die of the disease, making it the most deadly gynecologic malignancy. 1 Although more than 60% of cases are diagnosed in advanced stages (stages III and IV), stage I represents one quarter of all new epithelial ovarian cancer diagnoses, and the overall 5-year survival is reported to be between 70% and 89%. [2] [3] [4] Epithelial ovarian cancer staging is surgical and is based on the 1988 International Federation of Gynecology and Obstetrics (FIGO) staging criteria. 5 Stage IA encompasses all unilateral, unruptured ovarian cancers without surface involvement. Stage IB epithelial ovarian cancers are bilateral, unruptured, and without surface involvement. Epithelial ovarian cancers confined to the ovary are assigned to stage IC if there is evidence of capsule surface involvement or See related editorial on page 4. positive cytology in peritoneal washings obtained at time of exploration. In addition, if the capsule of a stage IA or IB cancer is ruptured either preoperatively or intraoperatively, the patient is upstaged to stage IC. When patients are managed only with surgery, the overall 5-year survival for stage IA approaches 94% and stage IB 92%, whereas 5-year survival for stage IC is 84% in some series. 2 For stage I epithelial ovarian cancer overall, the 5-year recurrence-free survival after appropriate staging and adjuvant chemotherapy approaches 85%. 6 The standard of care today for management of epithelial ovarian cancer includes surgical staging and tumor cytoreduction when indicated, followed by adjuvant platinum-based chemotherapy. 7 This approach has yielded improved disease-free survival and overall survival. 8 -11 Factors that delineate which early-stage patients are at highest risk for recurrence are used to determine whether to administer adjuvant chemotherapy. Important prognostic factors include grade, histologic subtype, and substage. 12 Optimal adjuvant treatment of high-risk early stage epithelial ovarian cancer continues to be debated (Markman M. Re: "Randomized phase III trial of three compared with six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study" [letter] . Gynecol Oncol 2007;105: 279 -80). 3 However, it is generally agreed that after comprehensive staging, well-differentiated or moderately differentiated stage IA cancers do not benefit from adjuvant chemotherapy, because their overall prognosis is excellent without adjuvant treatment. 9, 12, 13, 14 In addition, per the National Comprehensive Center Network guidelines, both comprehensively staged grade 1 and 2, stage IA and IB epithelial ovarian cancer can be observed. 15 For all other categories of stage I disease, adjuvant treatment is recommended.
One area of conflict is the prognostic significance of capsule rupture during surgery in a case that would otherwise be assigned to stage IA or IB. Several studies have suggested that intraoperative rupture of an intact capsule does not affect prognosis, 2, 16, 17 whereas others indicate intraoperative rupture is an independent predictor of decreased disease-free survival 18 -21 and worse overall survival. 19 Unfortunately, most of these studies are limited by inclusion of nonstaged or incompletely staged cases, lack of consistent adjuvant treatments, and lack of subset analyses of categories within stage IC tumors. These limitations make interpretation of the existing literature fraught with errors. We designed this retrospective study to investigate the effect of intraoperative capsule rupture on disease-free survival and disease-specific survival in patients with stage I epithelial ovarian cancer who were completely staged and all treated during the platinum chemotherapy era according to similar standards. Patients were excluded if they were referred for staging after the diagnosis was made elsewhere or distant in time from the diagnostic operative procedure or if they had preoperative drainage or cyst aspiration. All cases were either independently reviewed by a single gynecologic pathologist (Mayo Clinic) or re-reviewed by a gynecologic pathologist at tumor board as part of clinical decision making (The Ohio State University College of Medicine).
MATERIALS AND METHODS
For the purpose of identifying and separating the various indications for assignment to stage IC, we defined substages of stage IC as follows: ICr-patients who had intraoperative capsule rupture as their only stage IC qualification (eg, no surface involvement and negative cytology); ICs/w, no rupture-patients with surface excrescences and/or positive cytologic washings whose tumors were removed intact; ICs/w, with rupture-patients with surface excrescences and/or positive cytologic washings whose tumors also ruptured intraoperatively.
The primary outcomes chosen were disease-free survival and disease-specific survival. Disease-specific survival was chosen instead of overall survival because many patients with early stage disease who are rendered disease free will die from other causes without recur-rence. Cox proportional hazards, Kaplan-Meier estimation, log rank test, and 2 test were used for statistical analyses. Stepwise multivariable analysis was performed to determine factors significantly affecting disease-free survival. Due to the small number of patients who died from disease, multivariable analysis of factors affecting disease-specific survival was not performed. The JMP 7.0 (SAS Institute Inc., Cary, NC) statistical program was used for all analyses.
RESULTS
During the study interval, there were 161 patients diagnosed with surgical stage I epithelial ovarian cancer who underwent comprehensive surgical staging. All patients underwent immediate comprehensive surgical staging after intraoperative frozen section determination of cancer.
Substaging was as follows: 65 (40%) FIGO stage IA, 9 (6%) IB, and 87 (54%) IC. Thirty-eight (44%) of the stage IC cases would have been considered stage IA or IB if the tumor capsule had remained intact. Overall, for the 87 cases of IC disease, the reasons for upstaging were as follows: 38 (44%) secondary to intraoperative capsule rupture only (ICr); 26 (30%) due to ovarian surface involvement with tumor and/or positive cytology from washings and no intraoperative rupture of the capsule (ICs/w, no rupture); and 23 (26%) due to ovarian surface involvement with tumor and/or positive cytology from washings in addition to intraoperative rupture of the capsule (ICs/w, with rupture) (Table 1) .
Overall, 22 patients (14%) developed recurrent disease, and 12 patients (7%) died of disease. The median follow-up among the 139 patients alive at the time of last follow-up was 44.7 months (range 0.2-185 months, mean 54.1 months). MeanϮstandard deviation pelvic and paraaortic lymph node counts were 26.8Ϯ13.8 and 11.7Ϯ7.2, respectively.
In univariable analysis, capsule rupture portended a lower disease-free survival (hazard ratio [HR] 3.6, 95% confidence interval [CI] 1.5-8.9; Pϭ.004) ( Table 2 ) and a lower disease-specific survival (HR 4.1, 95% CI 1.3-15.4; Pϭ.018) ( Table 3) . When controlling for positive cytology, intraoperative capsule rupture remained a predictor of poorer disease-free survival (HR 4.2, 95% CI 1.8 -10.9; Pϭ.001).
There was similar disease-free survival (Pϭ.84, log rank) and disease-specific survival (Pϭ.97, log rank) among patients who were assigned to stage IC due to a single factor alone (eg, only positive cytology or surface involvement or capsule rupture). Among all stage IC cases, the shortest disease-free survival and disease-specific survival were observed in patients who had a combination of positive cytology and/or surface involvement along with intraoperative capsule rupture (ICs/w, with rupture). Patients classified as ICs/w, with rupture had significantly worse disease-free survival (HR 3.3, 95% CI 1.1-12.1; Pϭ.041) compared with ICs/w, no rupture patients. Disease-specific survival was not significantly different between these two cohorts; however, there were only three (of 26) ICs/w, no rupture patients and five (of 23) ICs/w, with rupture patients who died from disease, thus limiting power. Patients assigned to IC solely due to rupture (ICr) had outcomes similar to those assigned to IC due to surface involvement and/or positive cytology (ICs/w, no rupture) (Fig. 1 ).
There were 38 (44%) stage IC patients who were upstaged to IC from IA/B disease based solely on intraoperative capsule rupture (ICr). These patients all had negative cytologic washings before tumor manipulation as well as no ovarian surface excrescences on final pathology. There were five recurrences (13.2%) and three deaths from disease (7.9%) among the 38 ICr patients; there were four recurrences (5.4%) and only one death from disease (1.4%) among the 74 IA/B patients. In time-to-event analyses, differences in disease-free survival (HR 2.7, 95% CI 0.7-10.9; Pϭ.14) (Fig. 2) and disease-specific survival (HR 5.3, 95% CI 0.7-107.8; Pϭ.12) between stages IA/B and ICr were observed but they were not statistically significant. This also likely reflects the limited power due to the small number of events. Overall, disease-free survival was shorter (HR 5.0, 95% CI 1.9 -17.3; PϽ.001), and disease-specific survival was shorter (HR 10.6, 95% CI 2.0 -193.8; Pϭ.002), for combined stage IC cases compared with stage IA/B cases. Clear descriptions of the ovarian tumors' intraoperative mobility were available for 151 of 161 (94%) cases such that we could accurately classify them as either fixed or mobile. Nearly an equal percentage of tumors were described as mobile (46%) as were described as fixed (48%) in the operative notes (Table  1) . There was no correlation between tumor mobility and surface involvement of tumor (Pϭ.36, 2 ) or positive cytology (Pϭ.47, 2 ). There was a higher rate of capsule rupture when tumors were described by Table 3) .
In univariable analyses, having positive cytologic washings decreased disease-free survival (HR 5.2, 95% CI 2.1-12.3; PϽ.001) and disease-specific survival (HR 5.9, 95% CI 1.8 -19.3; Pϭ.005), whereas having ovarian surface excrescences alone had no effect on disease-free survival or disease-specific survival (Table 2 and 3) . Controlling for intraoperative capsule rupture, the presence of positive cytology remained a predictor of worse disease-free survival (HR 6.4, 95% CI 2.5-16.0; PϽ.001).
Twenty-six patients were stage IC based on surface involvement and/or positive cytologic washings but had their tumors removed intact without rupture. Fifteen (58%) had only positive cytology and no evidence of surface involvement, eight (31%) had surface involvement only and negative cytology, and three (11%) had both positive cytology and surface involvement. Twenty-three additional patients were stage IC based on surface involvement and/or positive cytologic washings and also sustained capsule rupture during surgery. Twelve (52%) had positive cytology and tumor rupture; eight (35%) had surface involvement and tumor rupture; and three (13%) had both positive cytology and surface involvement in addition to tumor rupture.
In univariable analysis, receiving platinum-based chemotherapy was not associated with worse diseasespecific survival or disease-free survival ( ). Chemotherapy was administered in substages of IC as follows: Icr-34 of 38 cases (89%); ICs/w, no rupture-18 of 26 cases (69%); ICs/w, with rupture-22 of 23 cases (96%). There was a significant difference in the percentage of patients receiving chemotherapy among all substages.
Thirteen stage IC patients did not receive platinum-based chemotherapy. Reasons for not receiving platinum-based chemotherapy among stage IC patients were as follows: stage Icr-one patient refused and two patients did not receive chemotherapy for reasons unknown; stage ICs/w, no rupture-one received intraperitoneal P32, one had recurrent melanoma, one died on postoperative day 18 from a myocardial infarction, and one did not receive chemotherapy for reasons unknown; and stage ICs/w, with rupture-1 received intraperitoneal P32. Intraperitoneal P32 was not considered equal to platinumbased chemotherapy. [22] [23] [24] An additional eight patients received follow-up at outside institutions and receipt of chemotherapy is unknown. Three were stage IA/B, one was stage ICr, and four were stage ICs/w, no rupture.
Despite adjuvant treatment, 4 (12%) of the 34 ICr patients who received chemotherapy developed disease recurrence, and three died from their disease. In addition, 17% (3 of 18) of stage ICs/w, no rupture cases that received chemotherapy and 36% (8 of 22) stage ICs/w, with rupture cases that received chemotherapy developed disease recurrence. Fifteen percent (6 of 40) of stage ICs/w cases overall (those with capsule rupture and those without) who received chemotherapy died of their disease. Nine percent (3 of 34) of ICr cases and only 3% (1 of 32) of IA/B cases who received platinum-based chemotherapy died of disease.
Just over one half of the epithelial ovarian cancers were FIGO grade 3 ( Table 1) . We dichotomized tumors as either low-grade (FIGO grade 1 or 2) or high-grade (FIGO grade 3) for analyses. In univariable analysis, higher grade demonstrated a tendency to affect disease-free survival but did not reach statistical significance (HR 2.3, 95% CI 1.0 -5.9; Pϭ.064). Higher grade did portend a worse disease-specific survival (HR 5.5, 95% CI 1.4 -36.1; Pϭ.011) ( Table 2) . Additionally, there was a higher likelihood of receiving platinum-based chemotherapy associated with highgrade tumor (PϽ.001, 2 ). The most common histology was endometrioid (37%), followed by clear cell (22%), serous (18%), mucinous (17%), and other (mixed, transitional cell, and seroanaplastic) histologies (6%). There was no difference in disease-free survival or diseasespecific survival based on histologic subtype.
DISCUSSION
The effects of intraoperative capsular rupture on outcomes in stage I epithelial ovarian cancer have been difficult to elucidate due to the conflicting published literature and the heterogenous populations of patients included in these reports leading to flawed conclusions. Most notably, prior publications have included, or been comprised of, a large percentage of incompletely staged patients, 2, 10, 16, 18, 19, 21 patients who received non-platinum-based chemotherapy 19 or radiation as their adjuvant therapy, 21 and the inclusion of borderline tumors. 16 The cohort of women that we studied was highly homogeneous, because all of them had invasive epithelial ovarian cancer, underwent complete staging procedures, and if adjuvant therapy was administered, it was a platinum-based regimen.
In this retrospective, two-institution study, we analyzed the importance of intraoperative tumor rupture on prognosis in a uniform cohort of early stage epithelial ovarian cancer. We observed both a shorter time to disease recurrence and shorter disease-specific survival associated with intraoperative capsule rupture both alone and when controlling for positive cytology, which was also an independent predictor of worse disease-free survival and disease-specific survival. While positive cytology was a significant predictor of worse prognosis, washings were collected before tumor manipulation and capsule rupture (if rupture occurred) suggesting that malignant cells within the pelvis and abdomen are an inherent finding at the time of surgery for some patients. Capsule rupture, however, may be preventable with careful surgical technique.
We noted a clinically significant difference in disease-free survival and disease-specific survival between stage IA/B and stage ICr patients; however, this difference did not reach statistical significance (Figure 2 ). We attribute this to the small number of recurrences and deaths from disease in both groups and while analysis of a larger number of IA/B and ICr patients is warranted, this factor should be considered when planning adjuvant therapy. The worst diseasefree survival and disease-specific survival were observed in patients who had tumor rupture in addition to surface excrescences and/or malignant cells present in their pelvic washings. Thus, it seems that intraoperative capsule rupture further worsens the prognosis of those women who are already stage IC based on the unalterable findings of surface involvement and/or positive cytology.
One of the strengths of our study is the restriction to cases that were comprehensively staged, including pelvic washings, hysterectomy, bilateral salpingo-oophorectomy, omentectomy, pelvic and paraaortic lymphadenectomy, and peritoneal biopsies. An additional strength of the study is that all patients treated with intravenous chemotherapy received platinumbased regimens. Despite our restrictions, our findings are consistent with the most recent published data which also suggests there is a worse prognosis for stage I patients who have intraoperative capsule rupture. 18 -21 A limitation in any retrospective surgical series is the dependence upon operative notes for intraoperative factors, such as the presence of peritumoral adhesions, which may also contribute to intraoperative rupture. In addition, when comparing stage IA/B cases to stage ICr cases, we lacked the power to show a statistically significant difference in diseasefree survival and disease-specific survival despite the HR of 2.7 and 5.3, respectively.
When considering why intraoperative capsular rupture might be an important prognostic factor, we developed several hypothesis-driven questions. First, is tumor fixation the true prognostic indicator and the capsule rupturing during removal simply a surrogate of tumor immobility? Although fixed tumors were more likely to rupture, neither recurrence nor death from disease were associated with mass immobility. Importantly, we also noted that tumor immobility did not correlate with surface involvement on final pathology. Second, are we seeing a prognostic effect of lag time between diagnosis (ie, laparoscopic salpingo-oophorectomy) and definitive staging? In this study, no patients were included whose tumors were removed for diagnosis and referred weeks later for definitive surgical management. All of the women in this study underwent immediate staging by a gynecologic oncologist and irrigation of the peritoneal cavity at the time of frozen-section diagnosis. This eliminates lag time as a factor.
We are left suggesting two reasonable concepts for why intraoperative rupture may affect outcomes. First, that intraoperative spread of viable tumor occurs at the time of rupture. This suggests very careful avoidance of rupture is warranted, and if it occurs, immediate and copious irrigation should be performed, perhaps before completion of staging operation to avoid seeding retroperitoneal spaces and then again at the end of surgery. A second reasonable
